Physician profile
Debra B Messner
NPI 1447407929
$3,241.53
in general payments reported to CMS, 2019-2025
25 companies · $738 in 2025
The $738 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $170 · 2022: $807 · 2023: $942 · 2024: $585 · 2025: $738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,264.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $513.14 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $387.14 | 2021-2025 | |
| Glaxosmithkline, LLC. | $346.86 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $329.49 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $253.43 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $251.69 | 2022-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $164.36 | 2022-2025 | Airsupra, Farxiga |
| Otsuka America Pharmaceutical, INC. | $162.23 | 2021-2024 | Rexulti, Abilify Maintena |
| Exact Sciences Corporation | $150.17 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $103.19 | 2022 | |
| Janssen Pharmaceuticals, INC | $88.53 | 2022-2025 | Xarelto, Spravato |
| Merck Sharp & Dohme LLC | $82.74 | 2021-2025 | Vaxelis, Gardasil 9, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.73 | 2022-2025 | Jardiance |
| Astellas Pharma US INC | $59.00 | 2022-2024 | Veozah |
| Xeris Pharmaceuticals, INC. | $47.62 | 2024 | Keveyis |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $46.69 | 2024-2025 | Voquezna |
| Nevro Corp. | $45.90 | 2023 | Senza |
| Sanofi Pasteur INC. | $31.07 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.58 | 2025 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $16.20 | 2021 | |
| Indivior INC. | $16.12 | 2021 | |
| Amarin Pharma, INC. | $15.39 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.19 | 2023 | Quviviq |
| Abbott Laboratories | $12.73 | 2022 | |
| Amgen INC. | $12.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Messner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.